Riccardo Braglia

Riccardo Braglia is the founder of GSTS Gui Sheng Tang.
Sinomedica SA, founded in 2001.
Mr. Braglia was the founder of Lyfebulb LLC, founded in 2014, and served as Director.
Mr. Braglia is also the founder of Fondazione Nuovo Fiore in Africa.
Current positions include Vice Chairman & Chief Executive Officer at Helsinn Holding SA since 2002; Chairman & Chief Executive Officer at Helsinn Healthcare SA since 2000; Chairman at Helsinn Birex Pharmaceuticals Ltd.; Chairman & General Partner at 3B Future Health Ventures SARL since 2016; Chairman at WS Fashion Holding SA since 2010; Chairman and General Partner at 3B Future Health Fund II S.C.
A. SICAV-RAIF; Executive Chairman at Helsinn SA; Group Vice Chairman at 3b Future Holding SA; Director at Helsinn Therapeutics (U.S.), Inc.; Director at Conquer Cancer Foundation of the American Society of Clinical since 2019; Director at Helsinn Advanced Synthesis SA; Independent Director at Medacta Group SA since 2020; Director at HAS Healthcare Advanced Synthesis since 2007; Director at Gui Sheng Tang.
Sinomedica Holding SA; Director at Fondazione Gabriele e Anna Braglia; Director at Fondazione per la ricerca sul cancro nel Ticino; Member at CEO Roundtable on Cancer, Inc.; Advisor at Windham Venture Management LLC since 2012; President at Lauro & Giavatto SA. Former positions include Director at Thorne Holding Corp.; Director at Swiss-American Chamber of Commerce from 2015 to 2021; Director at Thorne Research, Inc.; Advisory at New York Philharmonic from 2015 to 2019; Member of the board at WellnessFX, Inc. from 2012 to 2020; Board Member at Greenbone Ortho SRL from 2017 to 2020; Board Member at QuantuMDx Group Ltd. from 2017 to 2020; Member of the Board at Thorne HealthTech, Inc. from 2011 to 2023.
Education includes an MBA degree from the University of Bocconi, conferred in 1984.